Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial

Sculier, Delphine; Wandeler, Gilles; Yerly Ferrillo, Sabine; Marinosci, Annalisa; Stoeckle, Marcel; Bernasconi, Enos; Braun, Dominique L.; Vernazza, Pietro; Cavassini, Matthias; Buzzi, Marta; Metzner, Karin J.; Decosterd, Laurent A.; Günthard, Huldrych F.; Schmid, Patrick; Limacher, Andreas; Egger, Matthias; Calmy, Alexandra; Swiss HIV Cohort Study

doi:10.1371/journal.pmed.1003421

Scientific article

English

Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial

ContributorsSculier, Delphine; Wandeler, Gilles; Yerly Ferrillo, Sabine; Marinosci, Annalisa; Stoeckle, Marcel; Bernasconi, Enos; Braun, Dominique L.; Vernazza, Pietro; Cavassini, Matthias; Buzzi, Marta; Metzner, Karin J.; Decosterd, Laurent A.; Günthard, Huldrych F.; Schmid, Patrick; Limacher, Andreas; Egger, Matthias; Calmy, Alexandra

; Swiss HIV Cohort Study

Published inPLoS medicine, vol. 17, no. 11, e1003421

Publication date2020

Abstract

Background: Dolutegravir (DTG)-based dual therapy is becoming a new paradigm for both the initiation and maintenance of HIV treatment. The SIMPL'HIV study investigated the outcomes of virologically suppressed patients on standard combination antiretroviral therapy (cART) switching to DTG + emtricitabine (FTC). We present the 48-week efficacy and safety data on DTG + FTC versus cART.

Keywords

Adult
Anti-HIV Agents / therapeutic use
Emtricitabine / administration & dosage
Emtricitabine / therapeutic use
Female
HIV Infections / drug therapy
HIV Seropositivity / drug therapy
HIV-1 / drug effects
HIV-1 / genetics
HIV-1 / pathogenicity
Heterocyclic Compounds
3-Ring / adverse effects
3-Ring / therapeutic use
Humans
Male
Middle Aged
Oxazines / adverse effects
Oxazines / therapeutic use
Piperazines / adverse effects
Piperazines / therapeutic use
Pyridones / adverse effects
Pyridones / therapeutic use
Switzerland

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Virologie clinique (668)

Funding

Citation (ISO format)

SCULIER, Delphine et al. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL’HIV trial. In: PLoS medicine, 2020, vol. 17, n° 11, p. e1003421. doi: 10.1371/journal.pmed.1003421